Good morning. Today the story is the distance between price and reality: a $2 trillion rocket company that has never turned a profit, an oil market celebrating a deal that hasn't physically happened yet, a telehealth industry that serves your employer's budget before it serves your health, and a federal education overhaul designed to look like bureaucratic tidying. Let's go.

Nothing below is investment advice.

SpaceX went public at $2 trillion. The math doesn't close.

SpaceX sold 555.6 million shares at $135 each last Thursday, raising $75 billion in the largest IPO in history. Saudi Aramco's 2019 listing, the previous record, raised somewhere between $26 and $30 billion depending on whether you count the overallotment. SpaceX didn't just beat it; it lapped it. Shares closed up 19% at $160.95 on day one, pushing the market cap past $2 trillion.

The number the prospectus buried, and the financial press mostly de-emphasized: SpaceX reported a net loss of $4.3 billion in Q1 2026. The company has never posted a net profit. You are buying a $2 trillion business that is currently spending faster than it earns, on the premise that Starlink, Starship, and whatever Mars eventually requires will eventually justify the price. Keep that premise front of mind. It is, however, a wager on future performance rather than demonstrated returns.

Morningstar analysts Nicolas Owens and Suryansh Sharma valued SpaceX at $780 billion using a discounted cash flow model, citing "very high" uncertainty around strategic execution, AI buildout, and key-person risk. That $780 billion figure is less than 40% of what investors paid on day one. The gap is the entire argument.

The key-person dependency is structural. Elon Musk controls roughly 85% of shareholder voting power and holds both the chairman and CEO roles. That concentration isn't unusual for a founder-led company going public, but it means that whatever you think about Musk's political entanglements, his attention, or his judgment over the next decade, you have no mechanism to change course. You are along for the ride, explicitly.

The timing is also a signal. SpaceX is the first of three large AI-adjacent public offerings anticipated this cycle; OpenAI and Anthropic have both filed preliminary paperwork with the SEC, with listings potentially coming this fall. (We've covered both companies extensively, and neither has posted a profit either.) The sequencing matters: SpaceX sets the pricing register for what the public markets will accept on ambition alone. If the day-one pop holds as template, OpenAI and Anthropic will go out at multiples that would have been considered science fiction in 2023.

The honest read: SpaceX is building real things that work. Starlink has paying customers on every continent. Starship is the only heavy-lift vehicle with a credible path to Mars. The technology case is serious. The valuation case requires you to believe the company will grow into a price that is currently more than twice what the most rigorous independent analysts think it's worth, under a governance structure where public shareholders have almost no say. Know which bet you're making before you make it.

Oil dropped 13% on a deal that hasn't opened the strait yet.

President Trump and Iran announced an initial agreement to end more than three months of war and reopen the Strait of Hormuz, with a formal signing scheduled for Friday, June 20, in Switzerland. Trump declared "the deal's all signed" at the G7 in France. Brent crude fell to roughly $83 a barrel, West Texas Intermediate to roughly $80, down nearly 13% from mid-week levels. For context: the conflict pushed oil as high as $126. Before the war, it was trading in the $60s.

Here is the part the futures market is skipping: the Strait will not reopen on signing day. Trump's own Truth Social follow-up specified the Strait would reopen "for purposes of mine removal." Iran laid mines in the strait during the conflict, and those mines need to be physically cleared before commercial shipping can move through. Mine clearance takes time, specialized vessels, and careful coordination. There is no version of this where tankers are flowing freely on June 20.

Kevin Book, managing director at Clearview Energy Partners, noted that even after the Strait does reopen, a full return to prewar supply levels could take months, because production fields and refineries were taken offline or damaged during the fighting. The infrastructure story doesn't resolve on a diplomatic timeline. The deal covers the politics; the physics of reopening a major shipping corridor is a separate problem.

The memorandum of understanding extends the existing U.S.-Iran ceasefire for 60 days but leaves Iran's nuclear program, frozen assets, and sanctions relief unresolved for a second round of negotiations. Those items are the entire structural question of what kind of Iran the U.S. is normalizing relations with. The 60-day clock starts ticking on signing day, and the issues left on the table are precisely the ones that have collapsed prior agreements.

For you, the immediate consequence is a gas pump that moves before the tankers do. One report puts the war-era spike at up to $1.50 per gallon above the prewar average; even after last week's futures drop, NPR reports gasoline remains more than a dollar above where it was before the conflict. Relief is being priced before it has arrived at a single refinery. When the physical supply picture catches up with the diplomatic one, prices should fall further. But the interval between "deal announced" and "the strait is clear" is where assumptions go wrong.

Your employer hired a telehealth company to say no to your GLP-1. Your doctor has no say.

David Davis has a Zepbound prescription from his primary care doctor. His insurer, Blue Cross Blue Shield of Texas, required him to restart the process through a telehealth company called Vida Health before it would consider covering the drug. Vida then pushed him toward naltrexone and bupropion, two drugs not approved for his condition (obstructive sleep apnea), before it would approve Zepbound. Vida declined to comment on his specific case.

Davis's situation is the architecture. Telehealth companies like Vida Health are hired by employers precisely to contain what employers spend on obesity drugs. That mandate comes from Jayne Hornung, chief clinical officer at MMIT, quoted directly in NPR's reporting. The platform's first obligation is to the employer's budget. The patient's existing doctor, with years of clinical context, is not part of the conversation.

The GLP-1 market created the incentive structure that produced this. These drugs work, they're expensive, and estimates published in JAMA Cardiology (cited by Fierce Healthcare) put the number of U.S. adults eligible for semaglutide alone at more than 137 million. Employers looked at that figure and at the per-patient price tag and hired intermediaries to manage the exposure. The telehealth companies that used to sell diabetes prevention programs saw the opening and pivoted into the weight-loss market when GLP-1s became blockbusters.

Regulation is not keeping pace. On February 20, 2026, the FDA sent warning letters to 30 telehealth companies over misleading marketing claims about compounded semaglutide and tirzepatide; HHS referred Hims & Hers Health to the Department of Justice. That enforcement targets the consumer-facing, direct-to-patient end of the market. The employer-intermediary model, where the insurer inserts a cost-management layer between patient and prescriber, is a different problem and a less scrutinized one.

If you are currently on a GLP-1 or pursuing one through your employer's benefits: ask specifically whether the platform your insurer requires is clinically independent or employer-contracted. The answer changes what the platform's recommendations actually mean.

Briefly: the Education Department just lost its two most consequential offices

Today the Trump administration announced it will move the Office of Special Education and Rehabilitative Services (OSERS) to the Department of Health and Human Services, and the Office for Civil Rights (OCR) to the Department of Justice. OSERS manages federal oversight of the Individuals with Disabilities Education Act, the law guaranteeing disabled students access to an equitable public education. OCR is the office students and families use to file discrimination complaints based on disability, gender, race, and national origin.

Education Secretary Linda McMahon framed the OSERS move as designed to help individuals with disabilities reach "greater independence, key life skills, and meaningful employment." Denise Forte, president and CEO of Ed Trust, called it "another vindictive attempt to undermine public education," adding that HHS is not equipped to serve children with disabilities. The structural critique is direct: these two offices exist in a single department because the rights they enforce are educational rights. Splitting them across HHS and DOJ scatters the legal backstop across two agencies with different mandates, different cultures, and different budget fights. A parent whose child's IEP is being ignored now files a complaint against a school system with a federal office that primarily handles adult medical and social services. Whether that produces better or worse outcomes for students is genuinely unknown. What is certain is that it produces a different process, and different processes have different completion rates.

**Word of the Week: *Disequilibrium***

(noun, pronounced diss-ee-kwuh-LIB-ree-um) A state in which forces are out of balance, such that the system cannot remain stable at its current position. From the Latin dis (apart) + aequilibrium (equal weight).

Today's edition is a case study in the gap between what prices say and what conditions actually are. SpaceX trades at more than twice its independent valuation on the strength of a story that hasn't yet become earnings. Oil falls 13% on a deal that hasn't yet cleared a single mine from a strait that hasn't yet moved a single tanker. A telehealth platform approves or denies your medication while your actual doctor sits outside the room. Two federal offices that enforce educational rights get relocated under a framing of improved outcomes that the people closest to those rights don't believe. In each case, the official position and the underlying reality are pulling in different directions. Systems in disequilibrium don't stay there forever. They either correct or they break. Today's job is knowing which direction each of these is heading.